Endo International plc (NASDAQ:ENDP) shares fell to a low of $5.86 before closing at $6.03. Intraday shares traded counted 2.76 million, which was 13.98% higher than its 30-day average trading volume of 3.21M. ENDP’s previous close was $5.87 while the outstanding shares total 230.55M. The firm has a beta of 1.46, a 12-month trailing P/E ratio of 274.09. The stock’s Relative Strength Index (RSI) is 55.32, with weekly volatility at 5.30% and ATR at 0.29. The ENDP stock’s 52-week price range has touched low of $2.71 and a $10.89 high. The stock traded higher over the last trading session, gaining 2.73% on 06/01/21.
Investors have identified the Drug Manufacturers – Specialty & Generic company Endo International plc as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.41 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Endo International plc (ENDP) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For ENDP, the company has in raw cash 1.56 billion on their books with 200.34 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 2.5 billion total, with 1.4 billion as their total liabilities.
ENDP were able to record 227.11 million as free cash flow during the 08/09/2021 quarter of the year, this saw their quarterly net cash flow reduce by 179.84 million. In cash movements, the company had a total of 243.84 million as operating cash flow.
Potential earnings growth for Endo International plc (ENDP)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/09/2021 quarter of the year, Endo International plc recorded a total of 717.92 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with -14.28% coming in sequential stages and their sales for the 08/09/2021 quarter reducing by -5.89%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 305.29 million trying to sell their products during the last quarter, with the result yielding a gross income of 412.63 million. This allows shareholders to hold on to 230.55M with the recently reported earning now reading 0.17 cents per share. This is a figure that compared to analyst’s prediction for their 08/09/2021 (0.73 cents a share).
Having a look at the company’s valuation, the company is expected to record 2.10 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on ENDP sounds very interesting.
Is the stock of ENDP attractive?
In related news, Director, MONTAGUE WILLIAM P sold 9,033 shares of the company’s stock in a transaction that recorded on Mar 15. The sale was performed at an average price of 8.68, for a total value of 78,406. As the sale deal closes, the Director, Cooke Shane now sold 17,290 shares of the company’s stock, valued at 149,558. Also, 10% Owner, Endo International plc bought 7,344,955 shares of the company’s stock in a deal that was recorded on Dec 02. The shares were price at an average price of 88.50 per share, with a total market value of 650,028,518. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.10%.
3 out of 15 analysts covering the stock have rated it a Buy, while 9 have maintained a Hold recommendation on Endo International plc. 3 analysts has assigned a Sell rating on the ENDP stock. The 12-month mean consensus price target for the company’s shares has been set at $7.70.